Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO
Fierce Pharma
APRIL 23, 2024
As the BIOSECURE Act threatens to upend relationships with Chinese contractors and western biopharma companies operating in the U.S., Novartis has elected not to adopt a “wait and see” attitude.
Let's personalize your content